| Patents for C07K 7 - Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof (42,273) |
|---|
| 06/15/2005 | CN1205995C Hybrid polypeptides with enhanced pharmacokinetic properties |
| 06/14/2005 | US6906245 Introducing nucleotide sequence encoding variant of proto-porphyrinogen IX oxidase lacking FAD binding sequence; expressing and regenerating |
| 06/14/2005 | US6906194 Fluorescence assay for kinase activity |
| 06/14/2005 | US6906176 Polypeptide or use in the fibrinolysis, digestion and coagulation |
| 06/14/2005 | US6906171 Process for the deprotection of protected thiols |
| 06/14/2005 | US6906170 Anti-inflammatory peptides derived from IL-2 and analogues thereof |
| 06/14/2005 | US6906169 Immunogenic peptide composition comprising measles virus Fprotein Thelper cell epitope (MUFThl-16) and N-terminus of β-amyloid peptide |
| 06/14/2005 | US6906035 Useful for inhibiting microbial infection or growth, as well reducing the effects of endotoxemia |
| 06/14/2005 | US6906032 Cyclic peptidomimetic urokinase receptor antagonists |
| 06/14/2005 | CA2264585C Monoclonal antibodies that define unique meningococcal b epitopes and their use in the preparation of vaccine compositions |
| 06/11/2005 | CA2450540A1 Antimicrobial peptides with reduced hemolysis and methods of their use |
| 06/09/2005 | WO2005052590A1 High-throughput screening method for integrin antagonist and new peptide screened therefrom |
| 06/09/2005 | WO2005051981A1 Biologically active peptides comprising isoleucyl-valyl-threonyl-asparaginyl-threonyl-threonine (ivtntt) |
| 06/09/2005 | WO2005051799A2 Peptide increasing fusiogenic capacity of a gamete |
| 06/09/2005 | WO2005051367A1 Carboxamide and amino derivatives and methods of their use |
| 06/09/2005 | WO2005051327A2 Glycopegylated erythropoietin |
| 06/09/2005 | WO2005037859A9 Fluorescence assay for kinase activity |
| 06/09/2005 | WO2004108756A3 Sars coronavirus peptides and uses thereof |
| 06/09/2005 | WO2004098628A3 Synthetic peptide analogs of arg-pro-pro-gly-phe as selective inhibitors of thrombin and thrombin activation of protease activated receptors 1 and 4 |
| 06/09/2005 | WO2004043383A8 A new target for angiogenesis and anti-angiogenesis therapy |
| 06/09/2005 | US20050124794 Histidine-proline rich tropomyosin-related anti-angiogenic receptor polypeptide or peptide tor use in prevention and treatment of tumor |
| 06/09/2005 | US20050124788 Intermediates for lhrh antagonist synthesis, process for their production, and process for lhrh antagonist production |
| 06/09/2005 | US20050124787 Process for preparing water soluble phosphonooxymethyl derivatives of alcohol and phenol |
| 06/09/2005 | US20050124550 Compounds that modulate the glucagon response and uses thereof |
| 06/09/2005 | US20050124549 Method of modulating the proliferation of medullary thyroid carcinoma cells |
| 06/09/2005 | US20050124548 Tumor suppression gene; protein; anticancer agents; skin disorders; antiarthritic agenst |
| 06/09/2005 | US20050124547 Tau-conotoxin peptides |
| 06/09/2005 | US20050124544 Peptide decoys for the preparation of medicaments intended for the prevention or treatment of autoimmune pathologies or disorders linked to the appearance of antibodies directed against exogenous proteins |
| 06/09/2005 | US20050124535 Cyclic peptide nanotube structures for molecular scale electronic and photonic devices |
| 06/09/2005 | US20050123610 Composition of a polypeptide and an amphiphilic compound in an ionic complex and the use thereof |
| 06/09/2005 | US20050123597 Releasable linkage and compositions containing same |
| 06/09/2005 | DE4142157B4 Opioid-Peptide, Verfahren zu ihrer Herstellung und sie enthaltende pharmazeutische Zusammensetzung Opioid peptides, process for their preparation and pharmaceutical composition containing the |
| 06/09/2005 | CA2547140A1 Glycopegylated erythropoietin |
| 06/09/2005 | CA2546498A1 Peptide increasing fusiogenic capacity of a gamete |
| 06/08/2005 | EP1538164A1 RGD targeting moiety its production and use |
| 06/08/2005 | EP1538157A2 Isolation and use of SH3 binding peptides |
| 06/08/2005 | EP1537421A2 A method for the identification of drug targets |
| 06/08/2005 | EP1537230A1 Fluorescent enzyme assay methods and compositions |
| 06/08/2005 | EP1537137A2 Stabilized bioactive peptides and methods of identification, synthesis, and use |
| 06/08/2005 | EP1536834A2 Design of chemokine analogs for the treatment of human diseases |
| 06/08/2005 | EP1536818A2 Fibrinogen binding moieties |
| 06/08/2005 | EP1536813A2 Compositions and methods comprising protein activated receptor antagonists |
| 06/08/2005 | CN1625603A Genetic polymorphisms in the preprotachykinin gene |
| 06/08/2005 | CN1625561A Peptide purification |
| 06/08/2005 | CN1205220C Novel cyclosporins |
| 06/07/2005 | US6903184 Multiple antigenic peptides immunogenic against Streptococcus pneumonia |
| 06/07/2005 | US6903074 Cyclic polypeptides having high receptivity and selectivity for neurokinins and hormones, admininstered for prophylaxis of gastrointestinal disorders or cancers |
| 06/07/2005 | US6902720 Cyclic peptide structures for molecular scale electronic and photonic devices |
| 06/02/2005 | WO2005049834A1 Cell activator, hair growth stimulant and hair growth promoter |
| 06/02/2005 | WO2005049819A1 Antibacterial peptide and utilization of the same |
| 06/02/2005 | WO2005049638A2 Amniotic-derived peptide and uses thereof |
| 06/02/2005 | WO2005018575A3 Estrogen receptor modulators and uses thereof |
| 06/02/2005 | WO2005010027A3 Novel peptidic conjugates for alopecia preventive and curative treatment |
| 06/02/2005 | WO2005007681A3 Inhibitors of serine proteases, particularly hcv ns3-ns4a protease |
| 06/02/2005 | WO2005000192A3 Glycogen synthase kinase-3 inhibitors |
| 06/02/2005 | WO2004112572A3 Monitoring immunologic, hematologic and inflammatory diseases |
| 06/02/2005 | WO2004078098A3 Peptides associated with hla-dr mhc class ii molecules involved in autoimmune diseases |
| 06/02/2005 | US20050119454 Biosynthesis of amino acid sequences; rearrangement of peptides; schizophrenia; Parkinson's disease; analgesics; central nervous system disorders |
| 06/02/2005 | US20050119189 Inhibitors of serine proteases, particularly HCV NS3-NS4A protease |
| 06/02/2005 | US20050119187 Anti-fibril peptides |
| 06/02/2005 | US20050119186 Potent peptide inhibitors and methods of use |
| 06/02/2005 | US20050119176 Core structure polypeptide; libraries; inhibition of apoptosis; anticancer agents; autoimmune disease; skin disorders; restenosis |
| 06/02/2005 | US20050119167 Process for the preparation of cyclic peptides |
| 06/02/2005 | US20050118706 Polymer arrays |
| 06/02/2005 | US20050118678 Modified polypeptide comprising amphipathic alpha -helical structure for use in prevention and treatment of infection and cell proliferative disorders |
| 06/02/2005 | US20050118664 Comprises peptide doubly labelled via thiol groups with alkyleneamidotetramethylrhodamine (alkyleneamido-TMR); kits |
| 06/02/2005 | US20050118136 Polyaspartic acid or polyglutamic acid end capped by oligopeptides of various amino acid sequences; improved pharmacokinetics, bioavailability and water solubility of conjugated drugs |
| 06/02/2005 | US20050118109 Method for treating lung diseases associated with ventilation-perfusion mismatches |
| 06/02/2005 | US20050118101 Delivery across skin or blood brain barrier; such as N-(fluorescein-5-yl)-thioureido-N'-Adoa-(polylysine)7-NH2 TFA salt |
| 06/01/2005 | EP1536009A1 Hla-a24-restricted cancer antigen peptide |
| 06/01/2005 | EP1535070A1 Nano-sized optical fluorescence labels and uses thereof |
| 06/01/2005 | EP1535065A2 Neuroprotective synergy of erythropoietin and insulin-like growth factor |
| 06/01/2005 | EP1534853A2 Methods and kits for transferases |
| 06/01/2005 | EP1534750A2 Therapeutic uses of monoclonal antibodies to the angiotensin-ii type-1 receptor |
| 06/01/2005 | EP1534745A2 A genomic approach to identification of novel broad-spectrum antimicrobial peptides from bony fish |
| 06/01/2005 | EP1534332A2 Antibodies and uses thereof |
| 06/01/2005 | EP1534315A2 Increasing of the resorption of substances via skin and mucous membranes |
| 06/01/2005 | EP1534308A2 Peptides with growth inhibitory action |
| 06/01/2005 | EP1404362A4 Signal-1/signal-2 bifunctional peptide inhibitors |
| 06/01/2005 | CN1622992A Synthetic peptides and methods for treating cancer invasion and metastasis |
| 06/01/2005 | CN1622954A Intermediates for LHRH antagonist synthesis, process for their production, and process for LHRH antagonist production |
| 06/01/2005 | CN1622941A Glutaminyl based DPIV inhibitors |
| 06/01/2005 | CN1622830A Peptide-based compounds |
| 06/01/2005 | CN1622821A Method of stimulating growth and resistance to diseases of aquatic organisms |
| 06/01/2005 | CN1204257C New peptide fragments for protein purification |
| 05/31/2005 | US6900033 Angiotensin converting enzyme-2/like polypeptides and inhibitors for treating and/or prevention of hypertension, congestive heart failure, stroke and atherosclerotic heart disease |
| 05/26/2005 | WO2005047531A1 Assay for pkc-beta activation of phosphorylation of myosin heavy chain polypeptide |
| 05/26/2005 | WO2005047511A2 Bacterial expression of protease inhibitors and variants thereof |
| 05/26/2005 | WO2005047316A2 Insulin releasing peptides |
| 05/26/2005 | WO2005047314A2 Fgf-beta binding and supported peptides |
| 05/26/2005 | WO2005047313A1 Peptide or protein capable of binding lipid a and lps, dna coding for the peptide or protein, and utilizing the peptide or protein, lps adsorbent or lps poison neutralizer |
| 05/26/2005 | WO2005046710A2 Tgf-beta binding and supported peptides |
| 05/26/2005 | WO2005046709A2 Tgf - beta binding and supported peptides |
| 05/26/2005 | WO2005046575A2 Amino acid prodrugs |
| 05/26/2005 | WO2005023845A3 Cyclic peptides acting as urotensin-ii antagonists |
| 05/26/2005 | WO2005009363A3 Treatment of pre-cancerous conditions and prevention of cancer using pcdgf-based therapies |
| 05/26/2005 | WO2005009217A3 Diagnosis of pre-cancerous conditions using pcdgf agents |
| 05/26/2005 | WO2004062574A9 Improved linkers for radiopharmaceutical compounds |
| 05/26/2005 | US20050113562 Antibodies directed against prothrombin fragment F1+2, the preparation and use thereof |
| 05/26/2005 | US20050113304 Recombinant expression system for production of a peptide capable of inhibiting the protease activity of Botulinum toxin B or tetanus toxin which expression system comprises a nucleotide sequence encoding the peptide operably linked to a control sequence for effecting expression |